Biophytis Reveals New Preclinical Findings on Obesity Treatment

Biophytis has announced promising preclinical results for its drug BIO101, targeting mobility restoration in obesity. Presented at the Frailty and Sarcopenia Research Conference, these findings show that BIO101, combined with GLP-1, significantly improves muscle strength and endurance in obese mice models. This advancement addresses muscle contractility issues, a common struggle for 96% of obese individuals.

Previously, BIO101 demonstrated positive effects in human clinical trials. Despite existing GLP-1 treatments focusing on weight reduction, Biophytis aims to fill the gap in restoring muscle functionality, tackling a critical health challenge affecting nearly one billion globally. With these findings, Biophytis is eager to progress its Phase 2 OBA clinical trial, expanding the potential therapeutic landscape.